Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 835 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Plans for NCI’s Fiscal Year 2019 Budget December 18, 2018 Study presents an AI-guided approach to target cancer antigens October 1, 2025 Metastatic Breast Cancer Patient Denied Chemotherapy Treatment During COVID-19 Outbreak March 20, 2020 Deaf Football Team Makes History, Heads To School’s First Finals Game... November 24, 2021 Load more HOT NEWS Neratinib Plus Capecitabine Outperforms Lapatinib Plus Capecitabine in Asian Patients with... Political Interests Are A Major Adversary in the War on Women Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma... CAR22 Shows Durable Efficacy After a Single Infusion in Patients with...
